These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 2783557)

  • 21. Some approaches to improve the therapeutic effectiveness of adoptive chemoimmunotherapy with spleen cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.
    Weiskirch LM; Mokyr MB
    Int J Cancer; 1992 Apr; 51(1):84-92. PubMed ID: 1563847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Norepinephrine-mediated inhibition of antitumor cytotoxic T lymphocyte generation involves a beta-adrenergic receptor mechanism and decreased TNF-alpha gene expression.
    Kalinichenko VV; Mokyr MB; Graf LH; Cohen RL; Chambers DA
    J Immunol; 1999 Sep; 163(5):2492-9. PubMed ID: 10452985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generation of anti-MOPC-315 cytotoxicity in uneducated or in vitro educated spleen cells from normal or MOPC-315 tumor-bearing mice pretreated in vivo with Bacillus Calmette-Guérin.
    Braun DP; Mokyr MB; Dray S
    Cancer Res; 1978 Jun; 38(6):1626-32. PubMed ID: 647676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor.
    Gorelik L; Prokhorova A; Mokyr MB
    Cancer Immunol Immunother; 1994 Aug; 39(2):117-26. PubMed ID: 8044831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor.
    Ye QW; Mokyr MB
    Cancer Res; 1984 Sep; 44(9):3873-9. PubMed ID: 6611201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of polyethylene glycol 6000 on the generation of antitumor cytotoxicity in MOPC-315 tumor bearer spleen cells cultured in the presence or absence of inactivated stimulator tumor cells.
    Przepiorka D; Mokyr MB; Dray S
    Cancer Res; 1980 Dec; 40(12):4565-70. PubMed ID: 7438090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Importance of IL-10 for CTLA-4-mediated inhibition of tumor-eradicating immunity.
    Jovasevic VM; Gorelik L; Bluestone JA; Mokyr MB
    J Immunol; 2004 Feb; 172(3):1449-54. PubMed ID: 14734721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of protective antitumor immune response against a murine plasmacytoma not curable by alkylating-drug treatment.
    Ophir R; Jackman A; Relyveld EH; Ben-Efraim S
    Anticancer Res; 1990; 10(1):231-5. PubMed ID: 2334133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice.
    Mokyr MB; Kalinichenko T; Gorelik L; Bluestone JA
    Cancer Res; 1998 Dec; 58(23):5301-4. PubMed ID: 9850053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors.
    Mokyr MB; Hengst JC; Dray S
    Cancer Res; 1982 Mar; 42(3):974-9. PubMed ID: 6977410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transforming growth factor-beta-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy.
    Weiskirch LM; Bar-Dagan Y; Mokyr MB
    Cancer Immunol Immunother; 1994 Apr; 38(4):215-24. PubMed ID: 8168116
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface.
    Nio Y; Hirahara N; Minari Y; Iguchi C; Yamasawa K; Toga T; Tamura K
    Anticancer Res; 2000; 20(5A):3293-9. PubMed ID: 11062756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insight into the mechanism(s) through which TNF promotes the generation of T cell-mediated antitumor cytotoxicity by tumor bearer splenic cells.
    Gorelik L; Bar-Dagan Y; Mokyr MB
    J Immunol; 1996 Jun; 156(11):4298-308. PubMed ID: 8666801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurotransmitter suppression of the in vitro generation of a cytotoxic T lymphocyte response against the syngeneic MOPC-315 plasmacytoma.
    Cook-Mills JM; Mokyr MB; Cohen RL; Perlman RL; Chambers DA
    Cancer Immunol Immunother; 1995 Feb; 40(2):79-87. PubMed ID: 7882386
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-dose-melphalan-induced up-regulation of type-1 cytokine expression in the s.c. tumor nodule of MOPC-315 tumor bearers and the role of interferon gamma in the therapeutic outcome.
    Gorelik L; Mokyr MB
    Cancer Immunol Immunother; 1995 Dec; 41(6):363-74. PubMed ID: 8635194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potentiation of antitumor CTL response by GM-CSF involves a B7-dependent mechanism.
    Mokyr MB; Kalinichenko TV; Gorelik L
    Cell Immunol; 1997 Jun; 178(2):152-61. PubMed ID: 9225006
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of low-dose cyclophosphamide therapy on specific and nonspecific T cell-dependent immune responses of spleen cells from mice bearing large MOPC-315 plasmacytomas.
    Wise JA; Mokyr MB; Dray S
    Cancer Immunol Immunother; 1988; 27(3):191-7. PubMed ID: 3263205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.